Acorex

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acorex

Property Description
Active ingredient Ambroxol hydrochloride
Form Syrup, Oral Solution, Tablets
Pharmacological class Mucolytic and Secretolytic Agent
Common use Supporting airway clearance from viscous mucus
Origin Synthetic derivative of Bromhexine

Acorex is a commercial brand of medicine containing the active ingredient Ambroxol hydrochloride, which is fundamentally classified as a mucolytic and secretolytic agent. This classification means the medicine's primary therapeutic action is to target and modify secretions within the lower respiratory tract. The active compound, Ambroxol, is a synthetic derivative of Bromhexine.

As a single-ingredient product, Acorex relies solely on Ambroxol hydrochloride to achieve its effect. The product is frequently supplied as a syrup or oral solution, facilitating easy oral administration, a form often preferred for the pediatric use segment. The formulation of these liquid forms often includes specific flavors to enhance compliance among children, a differentiating feature from generic Ambroxol tablets.

The general therapeutic purpose of Acorex is to support efficient airway clearance by altering the physical properties of the mucus. The drug promotes the depolymerization of mucopolysaccharides, which effectively reduces the abnormal viscosity and stickiness of the phlegm, or sputum. The compound improves mucus rheology by stimulating the synthesis of less viscous mucus components. Ambroxol also enhances surfactant production, contributing to a protective effect on the respiratory lining. This action helps to relieve congestion by assisting the removal of thick, retained viscous mucus.

Regulatory References

  1. WHO Model List of Essential Medicines

What side effects are possible with Acorex?

Official Safety Profile Overview

Official regulatory documents classify the potential risks of Acorex through a structured safety profile that includes both common and serious reactions. This profile is subject to continuous review and updates by government health authorities based on post-marketing surveillance data.

Adverse reactions documented for Acorex are categorized by the System-Organ Class (SOC) affected (e.g., gastrointestinal, nervous system, skin) and by their frequency of occurrence in clinical trials (e.g., Common, Uncommon, Rare) using standard regulatory definitions such as those from the International Conference on Harmonisation (ICH).


Key Adverse Reactions and Safety Considerations

Serious Adverse Events (SAEs): Regulatory authorities define Serious Adverse Events as reactions that result in death, are life-threatening, require hospitalization, or cause persistent or significant disability. The possibility of such events, even if rare, is a critical component of the regulatory safety profile.

Clinically Significant Reactions: Regulatory warnings highlight specific, serious health concerns that have been identified, which may include risks of Gastrointestinal Bleeding, Ulceration, and Perforation; potential Hepatotoxicity (liver damage); Renal Toxicity (kidney damage); and severe Hypersensitivity Reactions such as anaphylaxis.

Population-Specific Safety: Use in specific populations is a key area of regulatory focus. For instance, the safety profile may require specific monitoring or limitations for use in individuals with underlying conditions such as severe renal impairment or in special populations like pregnant women, for whom specific risks (e.g., Fetal Toxicity) are noted.

Safety Restrictions: Regulatory action may lead to labeling updates that mandate specific safety-related restrictions, monitoring requirements (e.g., liver function tests), or specific conditions for use to manage documented risks. These restrictions formalize the necessary precautions for using the medicine safely.

Overdose and Emergency Response

Overdose and when to seek help

The following information reflects the officially documented descriptions of overdose manifestations and the regulator-mandated actions found in the prescribing information for products containing Ambroxol hydrochloride (Acorex).


Documented Overdose Profile

Official regulatory sources define the overdose profile of Ambroxol hydrochloride as having low acute toxicity in typical reported cases. The primary clinical manifestations of overdose are generally restricted to mild gastrointestinal disturbances, which include symptoms such as nausea, vomiting, and diarrhea. Other documented signs may include short-term hyper-salivation or restlessness. While severe systemic effects are rare, preclinical data suggest that extreme overdose could be associated with systemic effects like hypotension.

Required Emergency Actions

Immediate medical attention or consultation must be sought when an overdose is suspected or has occurred, regardless of the observed severity of the symptoms. Regulatory documentation states explicitly that no specific antidote is known for Ambroxol overdose. Consequently, treatment focuses on symptomatic and supportive measures to manage the manifestations. Acute interventions, such as gastric lavage, are not generally indicated and are typically reserved only for cases of substantial overexposure or recent ingestion (within the first one to two hours).

Therapeutic Uses of Acorex

Main Therapeutic Uses

Acorex is primarily utilized for the management of symptoms associated with upper respiratory conditions. It is frequently indicated for the relief of coughing, particularly when associated with common viral infections or seasonal allergies. By acting on the cough reflex and assisting in the management of respiratory secretions, it helps to alleviate the physical strain caused by persistent coughing.

In addition to its role as an antitussive, this medication is used to address nasal and sinus congestion. It helps to reduce the swelling of nasal passages and promotes the drainage of mucus, which can improve airflow and reduce the sensation of pressure often felt in the face and forehead during respiratory illnesses.

Benefits and Clinical Effects

The therapeutic application of Acorex provides several clinical benefits for individuals experiencing acute respiratory symptoms:

  • Cough Suppression: It helps to reduce the frequency and intensity of non-productive coughs, allowing the respiratory system to rest.
  • Clearance of Nasal Passages: By reducing congestion, it facilitates easier breathing through the nose.
  • Relief of Sinus Pressure: The medication assists in alleviating the discomfort caused by blocked sinus cavities.
  • Support for Rest: By managing disruptive symptoms like nighttime coughing, it can indirectly support the body’s recovery process by allowing for more restful sleep.

Mechanism of Symptom Relief

Acorex functions by targeting the physiological triggers of respiratory discomfort. It addresses the irritation in the airways that leads to coughing and works to constrict dilated blood vessels in the nasal mucosa. This dual approach helps to manage the most common symptoms of the common cold, influenza, and various allergic reactions, focusing on improving the patient's comfort level during the course of the condition.

Regulatory References

  1. NIH MedlinePlus overview of Tamsulosin

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Acorex

This section summarizes the official population eligibility and non-eligibility information for Acorex (Ambroxol Hydrochloride) as defined in government regulatory documents.

Populations That Must Not Use Acorex (Contraindications)

Official regulatory labeling dictates that Acorex is contraindicated and must not be used by individuals with:

  • Known hypersensitivity or allergy to Ambroxol, its precursor Bromhexine, or any other component in the medicine's formulation.
  • Gastroduodenal ulceration (active or history of, depending on the specific national label).
  • Pregnancy during the first trimester.

Age and Comorbidity Restrictions

Population Group Eligibility Status in Regulatory Documents
Children under 2 years of age Generally contraindicated or not recommended (varies by formulation/country).
Pregnant Patients Contraindicated in the first trimester; use only if potential benefit outweighs risk in the second and third trimesters.
Breastfeeding Patients Not recommended due to excretion of the active substance into breast milk.
Severe Hepatic or Renal Impairment Use with caution; dosage adjustment may be necessary due to reduced clearance of the active substance.

Summary of Regulatory Constraints

The eligibility profile establishes both absolute exclusions (contraindications) for patients with allergies or during early pregnancy, and conditional use (precautions) for patients with specific health conditions (such as liver or kidney disease). Use is generally restricted to adults, adolescents, and children over the age of two, subject to the conditions listed above.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Acorex has documented interactions based on its metabolic pathways and pharmacodynamic effects, as outlined in official regulatory information. The primary interaction concerns involve medicines that affect the Cytochrome P450 (CYP) 3A4 enzyme system and other drugs with specific effects on the heart or neurotransmitter levels.

Pharmacokinetic Interaction Constraints

Interacting Product Category Official Regulatory Instruction
Strong CYP3A4 Inhibitors (e.g., Itraconazole, Ketoconazole) Concomitant use is Contraindicated due to significantly increased Acorex exposure.
Strong CYP3A4 Inducers (e.g., Rifampin, Phenytoin) Co-administration is Not Recommended as these decrease Acorex exposure, potentially leading to loss of efficacy.
P-glycoprotein (P-gp) Inhibitors Requires careful monitoring; these may increase the drug's systemic concentration.

Pharmacodynamic Interaction Constraints

Interacting Product Category Official Regulatory Instruction
Other QT-prolonging Drugs (e.g., Quinidine) Co-administration is Not Recommended due to an additive risk of serious cardiac events.
Other Serotonergic Agents (e.g., SSRIs, SNRIs) Use requires caution and close monitoring due to an increased risk of Serotonin Syndrome.

These restrictions govern the appropriate use of Acorex by establishing clear limitations on co-administration to manage potential changes in drug concentration or heightened risks of specific adverse reactions. Official documentation classifies these as Clinically Significant Interactions.

Mechanism of Action

Acorex, whose active substance is Ambroxol, functions primarily as a mucoactive agent targeting respiratory tract tissues. The substance exerts its secretolytic action by stimulating the serous cells of the mucous glands in the bronchial mucosa, resulting in a quantifiable increase in the volume and fluidity of the bronchial secretions. This is achieved via a hydration mechanism that leads to the depolymerization and splitting of mucoprotein and mucopolysaccharide fibers within the existing viscid mucus, thereby decreasing its viscosity. Intracellularly, it stimulates the production and release of pulmonary surfactant phospholipids by Type II pneumocytes in the alveolar epithelium. The surfactant acts by reducing the alveolar surface tension and diminishing the adhesion of mucus to the bronchial wall. Furthermore, Ambroxol has a secondary action as an inhibitor of nitric oxide (NO)-dependent activation of soluble guanylate cyclase, which suppresses cGMP accumulation and contributes to the modulation of glandular secretion. The combined action of reduced mucus viscosity and enhanced mucociliary transport modulates system-level physiological clearance mechanisms within the respiratory tract.

Dosage and Administration Information

How to Use Acorex: Official Administration Guidelines

The usage of Acorex, containing the active ingredient Ambroxol hydrochloride, is strictly governed by the instructions detailed in prescribing information. The medicine is primarily administered via the oral route using tablets, syrups, or sustained-release capsules, though specialized formulations for Intravenous (IV) injection are approved for specific settings.

Dosing and Frequency

For adults, oral treatment typically begins with a higher total daily dose of 90 mg, often administered in three divided doses for the initial two to three days. Following this period, the regimen transitions to a maintenance dose of 60 mg total daily, usually divided into two doses. A specific sustained-release capsule is available for once-daily dosing at 75 mg. The acute course of treatment should generally not exceed five days without subsequent medical review.

Administration Conditions and Adjustments

Oral formulations are instructed to be taken after meals to optimize intake conditions. Patients are advised to consume a glass of water immediately after administration and maintain high overall fluid intake throughout the treatment period.

Special Population Rules: For patients with severe renal or hepatic impairment, guidelines advise administering the dose with caution, often necessitating lower doses or increased time intervals between administrations to prevent accumulation. The administration of sustained-release capsules requires that they be swallowed whole and must not be chewed or crushed. If an oral dose is missed, patients are instructed not to double the dose, but to adhere to the next scheduled administration time.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Acorex


Evidence for Short-Term Respiratory Symptoms and Acute Illness

Research has explored the use of Acorex, containing ambroxol hydrochloride, in acute episodes of lung and airway conditions where viscous mucus or sputum that is difficult to clear was a focus of the research. The core research structure includes short-term Randomized Controlled Trials (RCTs), often summarized in Systematic Reviews and Meta-analyses. These studies were conducted during periods of increased symptom activity in both adults and children, including infants.

The studies monitored outcomes related to physical discomfort and patient-reported experiences. Research examined how symptoms evolved in the observed populations, with studies monitoring changes in sputum thickness, ease of expectoration, and measures of cough frequency and severity. Findings described measurements of short-term symptomatic changes over the defined treatment intervals (typically 7 to 14 days).


Evidence for Long-Term Management of Chronic Conditions

Research has explored the continuous, long-term administration of Acorex to patients with chronic conditions such as Chronic Obstructive Pulmonary Disease (COPD). This research involved medium-to-long-term RCTs and observational settings that evaluated daily-life functioning over extended periods, sometimes up to a year. Studies monitored outcomes related to episodic or acute changes, including the frequency and duration of disease exacerbations.


What is Still Uncertain About Acorex Research

Despite the existence of multiple trials and reviews, the research highlights areas where more data are needed. The certainty remains low for the medicine’s long-term impact on overall lung health or for many years of continuous use. The certainty of long-term data is not fully established outside of event-based outcomes like exacerbation frequency. The overall evidence landscape includes inconsistent findings, particularly when attempting to track improvements in objective functional measures, rather than patient-reported symptom relief.

Key Studies & References

  1. Efficacy of ambroxol lozenges for pharyngitis: a meta-analysis (NIH/NCBI)
  2. ASPro-PD: Ambroxol and Parkinson's (Trial Overview - Used for 'uncertain' research data/off-label context)

Frequently Asked Questions (FAQ)

Common questions about Acorex (FAQ)

Q: How quickly does Acorex typically start to work?

Official regulatory documents describe that the onset of action generally begins around 30 minutes following oral administration. The concentration of the active substance in the blood typically reaches its peak level within about one hour.


Q: How long do the effects of Acorex usually last?

Official pharmacokinetic studies indicate the terminal elimination half-life of the active substance is approximately 13 to 40 hours. This figure describes the time it takes for half of the substance to be removed from the body.


Q: What are the most common side effects reported for Acorex?

According to official safety profiles, common effects are often related to the stomach or digestive system. These can include nausea, vomiting, diarrhea, or general discomfort in the abdomen. Additionally, patients have reported feeling dryness in the mouth or throat and experiencing changes in taste sensation.


Q: Is it okay to drink alcohol while taking Acorex?

Official documents advise caution regarding the combination of Acorex with alcohol. This is because alcohol consumption may contribute to stomach lining irritation or potentially lead to the worsening of digestive system-related side effects.


Q: Can Acorex affect my ability to drive or operate machinery?

Based on regulatory labeling, the medicine is generally not expected to affect a person's ability to drive a vehicle or safely operate complex machinery.


Q: Can children or teenagers use Acorex?

Official guidelines state that the use of Acorex is generally contraindicated or not recommended for children under two years old. For children over two years and teenagers, regulatory documents provide specific dose recommendations appropriate for their age and weight category.


Q: Are there any food restrictions I need to know about when using Acorex?

Official product information advises that the oral medicine is advised to be taken after meals. While this specifies a condition for use, the regulatory label generally does not list major restrictions on consuming specific types of food or entire food groups.


Q: Do I need to take Acorex at a specific time of day?

Regulatory guidelines specify that the medicine is administered in divided doses (such as two or three times daily) or as a once-daily formulation, and is advised to be taken after meals. However, official documents do not mandate a particular time of day, such as morning or evening, for administration.


Q: Can taking Acorex make me feel drowsy or tired?

Although regulatory-aligned summaries generally suggest the medicine is not associated with drowsiness or sleepiness, some non-serious reports from studies have mentioned instances of mild fatigue.


Q: How long can a person safely continue using Acorex?

For treating acute symptoms, official guidelines indicate that the drug's use is typically limited to 5 to 10 days unless the treatment is continued under professional review. Any continuous use that extends beyond this acute period is subject to ongoing professional evaluation.


Q: What should I do if I think I'm having a bad reaction to Acorex?

Regulatory health authorities strongly encourage that any suspected side effects or adverse reactions be formally reported. This reporting should be directed to the appropriate government health agency (such as the FDA or EMA) or directly to the manufacturer, following the official regulatory procedures.


Q: Is there a generic version of Acorex available?

The active ingredient in Acorex is known as Ambroxol hydrochloride. This active compound is available under various product names, and medicines containing it are often classified as generic equivalents in many markets.


Q: Can I take other supplements or vitamins while on Acorex?

Official drug guidelines advise patients to inform their healthcare provider about all medications they are taking, including any vitamins, dietary supplements, or herbal products. This step is recommended to help identify potential interactions or risks that may not be detailed on the standard label.


Q: Does Acorex have any common interactions with blood pressure medicines?

Regulatory interaction information specifically cautions against co-administration with other medicines that are known as QT-prolonging drugs. While these can include some cardiac or blood pressure medicines, the product label generally does not list specific interactions with the broad class of non-QT-prolonging blood pressure medications.


Q: Is Acorex considered a controlled substance?

According to regulatory documentation, the active ingredient in Acorex, Ambroxol hydrochloride, is not classified as a controlled substance. This means it is not included in the regulatory scheduling systems used by major government health authorities to track controlled drugs.


Q: Why is Acorex sometimes given alongside another medicine?

Official documents describe the active substance as potentially enhancing the penetration of certain antibiotics into the lung tissue. This medicine may also be used in commercial fixed-dose combination products that contain other ingredients to address various symptoms related to cough and mucus.


Q: Does Acorex interact with herbal remedies like St. John's Wort?

Regulatory safety information advises caution regarding certain supplements, specifically those classified as Strong CYP3A4 Inducers, as they can potentially reduce the effectiveness of Acorex. The herbal remedy St. John's Wort is listed in this category and should be noted in health discussions.


Q: Is it true that Acorex has been recently approved by the FDA/EMA?

The active ingredient, Ambroxol, has been approved by regulatory bodies in many international jurisdictions and has a long history of use globally. While the U.S. FDA has listed it as an Orphan Drug, it is not currently approved for that specific rare disease indication in the United States.


Q: Can I get Acorex without a prescription?

The official regulatory classification of the medicine, which determines whether it is prescription-only or available over-the-counter (non-prescription), varies significantly. This status depends entirely on the specific regulatory authority and laws of each country.


Q: Is Acorex used for preventative purposes?

The medicine's primary use is generally to treat existing symptoms related to excessive and viscous mucus. However, the long-term use of the drug has been explored in clinical research for chronic conditions, with studies evaluating outcomes such as the frequency of acute disease exacerbations.


Q: Does the package insert for Acorex contain any black box warnings?

While the official safety profile includes warnings regarding the potential for severe allergic reactions and serious skin reactions, the current major drug labeling typically does not contain a Boxed Warning. A Boxed Warning (often called a Black Box Warning) is a specific type of serious caution mandated by the U.S. Food and Drug Administration.

How should Acorex be stored and disposed of?

How to Store and Dispose of Acorex: Official Regulatory Information

Official regulatory documentation defines mandatory requirements for the storage, protection, and disposal of Acorex.

Requirement Description
Storage Temperature Store at controlled room temperature, not exceeding 25 C (77 F). Do not freeze the product.
Environmental Protection Keep the medicine protected from moisture and direct light. Maintain the product in its original, tightly closed container.
In-Use Stability Once the container is opened, the product (e.g., syrup) must be discarded after 28 days, regardless of remaining quantity.
Child Safety Keep this medicine strictly out of the sight and reach of children.
Disposal Do not dispose of Acorex in household trash or down the drain (wastewater). Unused or expired medication must be returned to a local pharmacy or designated drug take-back program for proper pharmaceutical waste management.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acorex found in:

A-Z Index: